DOT Mandates Observed Urine Tests While Oral Fluid Certification Lags

DOT Mandates Observed Urine Tests While Oral Fluid Certification Lags

Safety-sensitive transportation workers — commercial truck drivers, rail employees, airline crew, and pipeline operators — face a new requirement for directly observed urine collection in specific drug-testing scenarios, under a final rule the Department of Transportation published May 11, 2026, effective June 10, 2026.

The rule addresses a regulatory contradiction created by DOT’s May 2023 rule that authorized oral fluid (saliva) drug testing as an employer-selectable alternative and, in specific direct-observation scenarios, required it. Federal drug-testing regulations require at least two HHS-certified labs to process oral fluid specimens — one for primary screening, a different lab for split-specimen confirmation. As of the new rule’s publication, zero certified oral fluid labs exist. The rule resolves the conflict by substituting directly observed urine collection until certification arrives, with an 18-month grace period after HHS certifies a second oral fluid lab.

The Three-Year Bottleneck

The gap between regulatory approval and operational availability has widened since 2023. DOT’s May 2023 rule authorized oral fluid testing as an employer option, following federal scientific validation of the methodology’s accuracy and forensic defensibility. Oral fluid testing carries two properties that distinguish it from urine testing: collection is inherently observed since it occurs in front of the collector, removing chain-of-custody vulnerabilities, and it detects only recent use — typically within the preceding hours — rather than historical metabolite presence. Quest Diagnostics (DGX ), which markets a proprietary oral fluid collection platform, has reported that substituted urine specimens rose 370 percent between 2022 and 2023, a figure the American Trucking Association has used to press HHS for faster certification.

The testing-method distinction matters directly for cannabis workers. DOT’s drug-testing panel includes marijuana among the substances screened, and urine tests can detect cannabis metabolites for weeks after use. Oral fluid tests are sensitive to use within the preceding hours — a fundamentally different standard for transportation workers who use cannabis legally under state law during off-hours. Federal workers in safety-sensitive roles receive no insulation from the gap: DOT held its drug-testing line for safety workers after federal rescheduling, and marijuana remains a disqualifying substance regardless of state law or federal schedule status.

The new rule applies only to those scenarios where the 2023 rule specifically required oral fluid — primarily situations where a same-sex urine observer cannot be located at the collection site. In the vast majority of testing situations, employers retain discretion over specimen type, though in practice, all currently use urine given the certification gap.

Workers, Congressional Pressure, and an FDA Opening

The directly observed urine requirement has drawn criticism centered on workers with paruresis — commonly called shy bladder syndrome — a condition affecting an estimated 7 percent of the population that prevents urination under direct observation. Under DOT procedures, a worker who cannot produce a urine specimen within three hours is treated as having refused the test and removed from safety-sensitive duty. Return to duty requires completing a directly observed collection, a cycle that advocates say imposes discriminatory career barriers on affected workers.

Dr. Steven Soifer, co-founder of the International Paruresis Association, has argued publicly that each month without certified oral fluid testing extends harm to federal workers with the condition. That concern has gained congressional attention: in April 2026, six members of Congress wrote to HHS Secretary Robert F. Kennedy Jr., attributing the certification gap to FDA regulatory barriers — specifically, requirements that make it difficult for oral fluid testing devices to obtain clearance for use in federal drug testing programs.

That letter may be moving the needle. On May 1, 2026, the FDA published a notice announcing its intent to consider removing a premarket notification requirement that had applied to certain toxicology test devices — including cannabinoid test systems — when used in federal drug testing programs. If finalized, the change would reduce the regulatory clearance burden for manufacturers bringing oral fluid devices to federal testing markets, potentially removing a key obstacle on the path to certified labs. FDA’s comment period closes June 30, 2026.

The new DOT rule also updates terminology in its direct-observation provisions, replacing “gender” with “sex” in sections governing who may serve as a urine-collection observer, consistent with a January 2025 presidential executive order on federal gender-policy terminology.

Once HHS certifies a second oral fluid lab, DOT will publish a Federal Register notice marking the start of the 18-month grace period during which employers can continue conducting directly observed urine collections while building out oral fluid infrastructure. Employers already equipped for oral fluid testing during that window must use it rather than wait out the deadline.

Federal drug-testing rules affecting cannabis workers have more unresolved questions ahead. A pending transportation bill would separately establish a federal cannabis impairment standard for commercial drivers — another policy change in motion through a framework that has been authorizing alternatives faster than it can put them into operation.